You are here: Home » Companies » Results
Business Standard

Natco Pharma Q3 net down 26% to Rs 159 cr on flat revenue, fall in margins

Margin reduction of Oseltamivir in the US market cited as the major cause for the decline in profits during the quarter

BS Reporter  |  Hyderabad 

Profit and loss
Photo: Shutterstock

Hyderabad-based Limited has reported a 26.72 per cent decline in consolidated net profit to Rs 159.3 crore for the quarter ended December 2018, owing to flattish revenues and fall in margins.

The company's consolidated revenues grew by little over one per cent to Rs 580 crore for the quarter under review, as compared to Rs 573.6 crore for the same quarter in the previous financial year and marginally lower on a sequential basis. However, the total expenditure rose 26 per cent to Rs 375.3 crore, from Rs 297.2 crore in the year-ago period.

ALSO READ: Natco Pharma to enter agrochemicals, set up Rs 100 crore facility in AP

The company attributed the decline in profits during the quarter predominantly to margin reduction of Oseltamivir in the US market. Formulations exports, including profit share, contributed Rs 257 crore to the total revenues, according to the company. The board of directors recommended an interim dividend of Rs 3.50 per equity share of Rs 2 each.

ALSO READ: Natco Pharma shifts focus from US, to spend 70% funds in emerging markets

First Published: Tue, February 12 2019. 19:03 IST